Year |
Citation |
Score |
2020 |
Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Rys RN, et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Advances. 4: 2886-2898. PMID 32589730 DOI: 10.1182/Bloodadvances.2020001696 |
0.658 |
|
2019 |
Rushton C, Arthur SE, Alcaide M, Cheung M, Thomas N, Hilton LK, Michaud NR, Daigle S, Davidson J, Bushell KR, Yu S, Jain MD, Shepherd LE, Crump M, Mann KK, et al. Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP Blood. 134: 921-921. DOI: 10.1182/Blood-2019-127399 |
0.825 |
|
2019 |
Rushton C, Alcaide M, Cheung M, Thomas N, Arthur S, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Jain M, Shepherd L, Crump M, Mann K, Kuruvilla J, et al. IDENTIFYING MUTATIONS ENRICHED IN RELAPSED-REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE Hematological Oncology. 37: 35-36. DOI: 10.1002/Hon.4_2629 |
0.785 |
|
2018 |
Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leukemia & Lymphoma. 1-16. PMID 29295643 DOI: 10.1080/10428194.2017.1413186 |
0.791 |
|
2018 |
Law C, Aaron W, Austin R, Barath M, Callihan E, Evans T, Gamez Guerrero M, Hemmati G, Jones A, Kwant K, Lao L, Lemon B, Moldt K, Patnaik P, Sexton K, ... ... Yu S, et al. Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma Blood. 132: 3225-3225. DOI: 10.1182/Blood-2018-99-113921 |
0.361 |
|
2017 |
Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, et al. Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Scientific Reports. 7: 10574. PMID 28874686 DOI: 10.1038/S41598-017-10269-2 |
0.659 |
|
2016 |
Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, Mann KK, Assouline S, Johnson NA, Morin RD. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. Clinical Chemistry. PMID 27440511 DOI: 10.1373/Clinchem.2016.255315 |
0.777 |
|
2016 |
Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, et al. Phase 2 study of panobinostat +/- rituximab in relapsed diffuse large B cell lymphoma and biomarkers predictive of response. Blood. PMID 27166360 DOI: 10.1182/Blood-2016-02-699520 |
0.793 |
|
2015 |
Morin RD, Assouline SE, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Holm Nielsen T, Petrogiannis-Haliotis T, Crump M, Tosikyan A, Grande BM, et al. Genetic landscapes of relapsed and refractory diffuse large B cell lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26647218 DOI: 10.1158/1078-0432.Ccr-15-2123 |
0.69 |
|
2015 |
Nielsen JS, Sedgwick C, Shahid A, Zong Z, Brumme ZL, Yu S, Liu L, Kroeger DR, Treon SP, Connors JM, Gascoyne RD, Berry BR, Marra MA, Morin RD, Macpherson N, et al. Toward personalized lymphoma immunotherapy: Identification of common driver mutations recognized by patient CD8+ T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26631611 DOI: 10.1158/1078-0432.Ccr-15-2023 |
0.76 |
|
Show low-probability matches. |